IMV has developed a novel depot-based vaccine platform that can be used with a variety of antigens and adjuvants, which can exhibit rapid and enhanced immune responses following a single dosage. This project will use cell tracking via molecular MRI to explore the immune cell migration in real time in an animal model of cancer, […]

Immunovaccine Inc. is developing cancer vaccines using the company’s DepoVaxTM vaccine technology. DepoVax is a patented formulation that displays excellent tumor control and provides a long lasting and specific effect. The way by which this vaccine exerts its effect is unclear but the translational team at Immunovaccine is determined to discover its mechanism of action […]

Immunovaccine Inc. is developing immune therapies for cancer using the company’s DepoVaxTM vaccine technology. DepoVax is a patented formulation provides controlled and prolonged exposure of antigens and adjuvants to the immune system, resulting in a strong, specific and sustained immune response. Immunovaccine’s translational research team is focused on improving responses in advanced cancers by combining […]